PATENTS &
DRUG CANDIDATES
Anti-Inflamation
May 2024
Curadev announces the publication of its PCT application covering heterocyclic inhibitors of Cdc-like Kinases
February 2023
Curadev announces the publication of its PCT application covering small molecule STING antagonists
February 2023
Curadev announces the publication of its PCT application covering small molecule urea derivatives as STING antagonists
Cancer Metabolism
January 2021
Curadev announces the publication of its PCT application covering small molecule ACSS2 inhibitors
Immune Oncology & Host Immunity
May 2024
Curadev announces the publication of its PCT application covering pyridone and pyrimidinone inhibitors of hematopoetic progenitor kinase 1
December 2019
Curadev announces the publication of its PCT applications claiming ADCs and other conjugates for its small molecule STING activator program
December 2019
Curadev announces the publication of its PCT application covering a unique small molecule STING activator chemotype
December 2018
Curadev announces the publication of three PCT applications covering distinct small molecule STING activator chemotypes
June 2018
Curadev files three PCT applications covering distinct small molecule chemotypes in its STING activator program CDV015
May 2018
Certificates of grant received from major international markets for the Curadev small molecule IDO and TDO dual inhibitor patent
February 2016
Curadev announces the publication of its third PCT application covering small molecule inhibitors of the kynurenine pathway
November 2014
Curadev announces the publication of its second PCT application covering small molecule inhibitors of the kynurenine pathway
September 2014
Curadev announces the publication of its first PCT application covering small molecule inhibitors of the kynurenine pathway
Drug Delivery and Diagnostics
December 2021
Curadev announces the publication of PCT application titled Rapid Method for Genotyping STING variants in human individuals
June 2021
European Patent Office upholds Curadev's cyclodextrin patent for new composition of matter
April 2018
Certificates of grant received from major international markets for the Curadev cyclodextrin derivative patent
January 2015
Curadev Pharma files a PCT application in its sponsored program with the University of Greenwich, UK
RECOGNITION
August 2021
Curadev is in Industry Outlook Magazine's list of the top 10 Biotechnology companies in India
Curadev's abstract entitled "CRD5500: LB061 was selected as “The most interesting one for the session on targeted immunotherapeutics presenting the landscape of research in Antibody Drug Conjugate (ADC) and Small Molecule Immunotherapy (SMI)” at AACR meeting held in Atlanta, Georgia
Success story of Curadev was featured on IIT, Kanpur website
April 2016
Curadev received funding approval from the Department of Biotechnology, India, under its SBIRI scheme
20 companies chosen as India's Emerging 20 by London Partners. Leaders of these companies were invited to open the London Stock Exchange
December 2011
Curadev’s In-House R&D unit received official recognition by the Department of Scientific and Industrial Research (DSIR)
September 2011
Curadev received permission to operate its vivarium from the CPSCEA, Ministry of Environment and Forestry, Government of India
September 2011
Curadev received permission to use radioactivity in its dedicated R&D lab from the Atomic Energy Regulatory Board, Government of India
March 2011
Curadev receives World Bank funding under the Sponsored Research and Development (SPREAD) Programme administered by the Technology Finance Group of ICICI Bank, headed by Mr. Jaisingh Dhummal. The objective of this program is to stimulate technology development through private investment in R&D and strengthen industry & technology institution (TI) collaboration. The Curadev project was selected based on its innovative content, likely impact and commercial value
OUTLICENSING &
STRATEGIC PARTNERSHIPS
April 2020
Curadev and Karyopharm, USA sign a drug discovery collaboration agreement under which Curadev will select a target for co-development until Phase 1 clinical trials before handing the drug candidate over to Karyopharm for further development
March 2020
Curadev and Bayer, Germany, sign a research collaboration and license agreement to develop novel STING antagonists
September 2019
Curadev receives first milestone payment from the out-licensing of its novel small molecule STING agonist to Takeda Pharmaceuticals
May 2019
Curadev announces licensing of its patents covering its novel small molecule STING agonists to Takeda Pharmaceuticals
May 2013
Curadev partners its dual kinase inhibitor program with Medivation, Inc, USA
September 2012
Curadev receives first milestone payment in its immune oncology small molecule collaboration with Endo Pharma
October 2011
Curadev signs extensive research collaboration deal with Medivation, Inc, USA
April 2011
Curadev announces research collaboration and licensing agreement to develop cancer immunotherapeutic with Endo Pharma
ACADEMIC
COLLABORATIONS
October 2020
Curadev initiates a collaboration with clinicians at Christian Medical College, Vellore to study kynurenine levels in dengue patients
July 2020
Curadev initiates a collaboration with Dana Farber Cancer Institute to identify drug combinations and patient populations that would benefit from Curadev’s advanced pre-clinical immune-oncology drug candidates
October 2016
Curadev initiates a collaboration with INSERM’s Professor Pierre Gressens, a leading clinician neuroscientist to identify drug targets underlying CNS pathologies
July 2011
Curadev signs research collaboration with the University of Greenwich. to create novel process improvements for a range of commercially valuable pharmaceuticals
March 2011
Curadev signs an agreement with the SIDBI incubation Center at the Indian Institute of Technology, Kanpur, (IITK)
COMPANY &
PEOPLE
February 2024
Curadev Announces First Treatment Cycle Completion for the First Patient Dosed in a Phase 1 a/b Clinical Trial of its Allosteric STING Agonist CRD3874-SI in Patients with Advanced Cancer at Memorial Sloan Kettering Cancer Center in New York
Read more...
February 2024
Curadev's Differentiated Next Generation STING Agonist CRD3874-SI
Read more...
April 2023
Curadev Pharma's Corporate Social Responsibility (CSR) projects- an update
Read more...
March 2023
Initiatives undertaken by Curadev under its Recognising Excellence campaign
Read more...
January 2023
Curadev Pharma announces the formation of its Clinical Advisory Group (CAG)
Read more...
December 2022
Curadev Pharma Receives FDA 'Study May Proceed' Letter for its Investigational New Drug Application of CRD3874, an IV-Administered STING Agonist for the treatment of advanced/metastatic solid cancers
Read more...
November 2022
Curadev Pharma joins NBEC to boost Indian Biotech Start ups: Sponsors Cash Prize for the second year in a row
Read more...
SEPTEMBER 2022
Curadev has sponsored a two-day seminar "Modern Trends in Technology" organized by Department of Microbiology, St. Xavier's College, Kolkata
View image...
AUGUST 2022
Curadev has sponsored the In-House Chemistry symposium organized by Shiv Nadar University from 26th-27th August 2022
View image...
January 2022
Curadev announces the formation of its Clinical Advisory Group (CAG) to provide guidance in the design and execution on oncology clinical trials
September 2021
A tree plantation drive was carried out by the Curadev Team in Noida Authority Park. The aim of the event was to create awareness and protect the environment by motivating everyone to take care of the surroundings we are part of
View image...
August 2021
As part of its focus on recognizing and promoting excellence, Curadev has sponsored the Gold Medal awarded to the top ranked Masters student of the Pharmacology & Toxicology department at the National Institute of Pharmaceutical Research and Training at Guwahati (NIPER, Guwahati)
August 2021
Curadev has partnered with C-CAMP (Centre for Cellular and Molecular Platforms) for National Bio Entrepreneurship Competition (NBEC), 2021
Read more...
November 2020
Diwali Donation Camp: As part of Personal Social Responsibility (PSR), team Curadev has donated clothing, footwear and stationery at large to NGO "Goonj"
January 2020
Curadev celebrates its 10th anniversary
May 2017
Professor Satyajit Rath has joined Curadev’s Scientific Advisory Board
Read more...
October 2016
Dr. Shyamala Mani has joined Curadev as Director R&D
Read more...
April 2016
Dr. David Pryde has joined Curadev as Director R&D bringing his extensive experience in drug discovery to the team
Read more...
January 2016
Curadev announces the incorporation of Curadev UK
June 2015
Dr. Sourav Basu has joined Curadev as Vice President (R&D)
Read more...
October 2012
Curadev Pharma is 1000 days young
CONFERENCES &
MEETINGS
2024
Senior Representatives of Curadev attended:
-
The Annual J.P. Morgan Health Care Conference, San Francisco, USA
-
10th Immunotherapy of Cancer Conference, Munich, Germany where Curadev presented posters titled : Discovery of CRD 1601, a potent and selective HPK1 inhibitor with robust in vivo anti-cancer activity and CRD3874-SI: a novel allosteric STING agonist with high systemic tolerability
-
The Annual Meeting of the American Association of Immunologist, Chicago where Curadev presented posters titled: COMPOUND 1 is a first-in-class small molecule cGAMP competitive oral STING antagonist that reduces lung inflammation and fibrosis in chronic bleomycin and silica mouse models and COMPOUND 2 is a first-in-class small molecule cGAMP competitive oral STING antagonist that reduces neuroinflammation in mouse models.
-
The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA
-
The Annual meeting of BIO, San Francisco, USA
2023
Senior Representatives of Curadev attended:
-
The Annual J.P. Morgan Health Care Conference, San Francisco, USA
-
The Annual meeting of the American Society for Cancer Research (AACR), San Diego, CA
-
The Society for Immunotherapy of Cancer (SITC), San Diego, USA where Curadev presented poster titled: Systemic delivery of novel, allosteric STING agonist CRD3874-SI leads to robust anti-cancer activity by generating pro-inflammatory Type I IFN signals while blocking proton channel mediated toxicity
2022
Senior Representatives of Curadev attended:
-
The Annual J.P. Morgan Health Care Conference, San Francisco, USA
-
The Annual meeting of the American Society for Cancer Research (AACR), New Orleans, Louisiana where Curadev presented poster titled :Intravenous administration of the small molecule STING agonist CRD5500 elicits potent anti-tumor immune responses in cold tumors and CRD1600 is a potent HPK-I inhibitor with robust immune modulatory properties
2021
Mr. Manish Tandon was invited as a Guest Speaker in the virtual event celebrating World Intellectual Property Week co-organized by FICPI, INTA, AIPPI, APAA, and Lex Witness
2020
Senior Representatives of Curadev attended:
-
The Annual J.P. Morgan Health Care Conference, San Francisco, USA
Senior Representatives of Curadev were invited as speakers:
-
Dr. Arjun Surya gave a talk at the Annual Biological Sciences and Bioengineering (BSBE) Symposium in IIT, Kanpur
-
Dr. Arjun Surya was invited as a Guest Speaker in the "International Conference on Drug Discovery" organized at BITS Pilani, Hyderabad from 29th February to 2nd March
2019
Senior Representatives of Curadev attended:
-
The Annual meeting of the European Society for Medical Oncology (ESMO), Barcelona, Spain
-
The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA
-
The Annual meeting of BIO, San Francisco, USA
-
The Annual meeting of the American Society for Cancer Research (AACR), Atlanta, USA. Curadev presented poster titled: CRD5500: A versatile small molecule STING agonist amenable to bioconjugation as an ADC
-
The Mastering Medicinal Chemistry Conference, Boston, USA
-
The Annual J.P. Morgan Health Care Conference, San Francisco, USA
2018
Senior Representatives of Curadev attended:
-
The Society for Immunotherapy of Cancer (SITC), Washington, D.C., USA
-
BIO-Europe, Copenhagen, Denmark
-
The Annual BIO meeting, Boston, USA
-
The Annual meeting of the European Society for Medical Oncology (ESMO), Barcelona, Spain
-
The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA
-
The Annual meeting of the American Society for Cancer Research (AACR), Chicago, USA. Curadev presented poster titled: Small molecule ACSS2 inhibitors target acetate metabolizing tumor cells in hypoxic conditions
-
The Annual J.P. Morgan Health Care Conference, San Francisco, USA
-
Researcher Summit organized by DBT and CRUK
2017
Senior Representatives of Curadev attended:
-
The Society for Immunotherapy of Cancer (SITC), Washington, D.C., USA
-
The Asia Congress of the European Society for Medical Oncology (ESMO), Singapore
-
The Annual BIO meeting, San Diego, USA
-
The Tumor Immunology and Immunotherapy meeting of the in Boston, USA
-
The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA
-
The Annual meeting of the American Society for Cancer Research (AACR), Washington,DC, USA. Curadev presented poster titled: Novel small-molecule human STING agonists generate robust Type I interferon responses in tumors
-
The Annual J.P. Morgan Health Care Conference, San Francisco, USA
-
The Keystone Symposium on Tumor Metabolism and Hypoxia, Whistler, Canada
2016
Senior Representatives of Curadev attended:
-
The Annual meeting of the American Society for Clinical Oncology (ASCO), Chicago, USA
-
The Annual meeting of the American Society for Cancer Research (AACR), New Orleans, USA where Curadev and Roche scientists presented a jointly authored poster titled: RG70099: A novel, highly potent dual TDO/IDO1 inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment.
-
The Mastering Medicinal Chemistry Conference, Boston, USA
-
The Society for Immunotherapy of Cancer (SITC), Washington, D.C., USA
-
The Asia Congress of the European Society for Medical Oncology (ESMO), Singapore
-
The Annual BIO meeting, San Francisco, USA
2015
Senior Representatives of Curadev attended:
-
The Annual BIO meeting, Philadelphia, USA
-
The Immunotherapy of Cancer (ITOC) conference in Munich, Germany
2014
Senior Representatives of Curadev attended:
-
The Tumor Immunology and Immunotherapy meeting of the American Society for Cancer Research (AACR) in Orlando, USA where Curadev presented a poster titled: a small molecule dual inhibitor of TDO and IDO
-
The Annual BIO meeting, San Diego, USA
-
The Annual BIO Asia International Conference meeting, Tokyo, Japan
-
The Immunotherapy of Cancer (ITOC) conference in Munich, Germany
2013
Senior Representatives of Curadev attended:
-
The Annual BIO meeting, Chicago, USA